iPSC-Derived Dopaminergic Transplants Demonstrate Safety and Motor Improvement in Parkinson’s Disease.
Phase I/II trial published in Nature shows biologic activity and clinical benefit without serious adverse events.
TribeMD
4 min read
August 5, 2025
Carregando conteúdo…
Psychiatry
Sources
- Doi D, Mori E, Itakura G, et al. Allogeneic transplantation of iPSC-derived dopaminergic progenitors in Parkinson’s disease: a phase I/II clinical trial. Nature. 2025;623(8015):512–521. doi:10.1038/s41586-025-08700-0.
Highlights
SnackableHealth® |Non-cardiac effects in HELIOS-B trial: gastrointestinal symptoms and quality-of-life signals discussed by Drs. Mike Gibson and Tony Urey
ASCO GU® 2026
Trastuzumab deruxtecan (T-DXd) Provides Significant Clinical Benefit Over Trastuzumab emtansine (T-DM1), Marking a Potential Shift in the Therapeutic Standard for HER2+ Breast Cancer
SnackableHealth® |Non-cardiac effects in HELIOS-B trial: gastrointestinal symptoms and quality-of-life signals discussed by Drs. Mike Gibson and Tony Urey
ASCO GU® 2026
Trastuzumab deruxtecan (T-DXd) Provides Significant Clinical Benefit Over Trastuzumab emtansine (T-DM1), Marking a Potential Shift in the Therapeutic Standard for HER2+ Breast Cancer